The biggest challenge for a roll-up's management is balancing M&A execution with operations. Teams often excel at one but neglect the other. Successful platforms require a leadership blend, sometimes through a dual-CEO structure, to cover both hunting for deals and managing the growing core business.

Dan Caruso argues against the common investor practice of tracking post-acquisition performance of individual deals. This prevents true integration and synergy capture. Instead of keeping assets separate for accounting purposes, acquirers should immediately "mash them together" into one unified system, focusing on the aggregate value creation of the combined platform.

Large roll-up platforms are failing their sale processes because buyers uncover a lack of true integration. Using data warehouses to aggregate data from disparate ERPs is no longer acceptable; buyers see this as a red flag indicating a disconnected operation that lacks real synergies.

Many M&A teams focus solely on closing the deal, a critical execution task. The best acquirers succeed by designing a parallel process where integration planning and value creation strategies are developed simultaneously with due diligence, ensuring post-close success.

By the time a strategic acquirer enters due diligence, the desire to do the deal is already high. The process's primary purpose is not to hunt for deal-breakers but to confirm key assumptions and, more importantly, to gather the necessary data to build a robust and successful integration plan.

Before deploying AI across a business, companies must first harmonize data definitions, especially after mergers. When different units call a "raw lead" something different, AI models cannot function reliably. This foundational data work is a critical prerequisite for moving beyond proofs-of-concept to scalable AI solutions.

The M&A market has shifted. Buyers no longer accept simple revenue aggregation. They now conduct deep diligence to disaggregate organic from inorganic growth, demanding proof of a sustainable growth engine beyond just making acquisitions.

A decade of active M&A left large pharmaceutical companies with a tangled mess of disparate technology platforms and data standards. The immense difficulty of integrating these acquisitions became a primary catalyst for investing in unified, scalable data foundations and modern IT infrastructure.

Failing to integrate acquired businesses onto a unified set of systems (ERP, CRM, accounting) will directly reduce your company's valuation at sale. Acquirers price in the future cost and risk of integration. The speaker estimates his unintegrated portfolio cost him an additional 1-2x EBITDA multiple on his exit.